^
Association details:
| Biomarker: | PRMT5 overexpression |
|---|---|
| Cancer: | Retinoblastoma |
| Drug: | EPZ015666 (PRMT5 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
EPZ015666, a selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an antitumour effect in retinoblastoma
Published date:
10/06/2020
Excerpt:
Our study showed that PRMT5 was overexpressed in retinoblastoma and played an important role in retinoblastoma cell growth. EPZ015666 is a novel PRMT5 inhibitor, and we found that it inhibited retinoblastoma cell proliferation and led to cell cycle arrest at the G1 phase.
DOI:
https://doi.org/10.1016/j.exer.2020.108286
